Overview
Burcon fiscal Q2 revenue grows 783% yr/yr, driven by protein sales
Burcon achieved first commercial production of canola and fava proteins
Outlook
Burcon reaffirms 2025 revenue target of C$1-3 mln
Company expects 2026 revenue to exceed C$10 mln
Burcon sees continued revenue acceleration and margin expansion into 2026
Result Drivers
COMMERCIAL PRODUCTION - Achieved first commercial production of Puratein® C canola protein and FavaPro™ fava protein
CUSTOMER PIPELINE - Burcon advanced its robust customer pipeline with over 200 projects under evaluation
Key Details
Press Release: ID:nNFC8K35Td
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)